2658-6533Research Results in Biomedicine2658-653310.18413/2313-8955-2017-3-1-24-30995Archive categoriesEFFICIENCY OF CHEMOPROPHYLAXIS OF TB IN HIV-POSITIVE PATIENTSEFFICIENCY OF CHEMOPROPHYLAXIS OF TB IN HIV-POSITIVE PATIENTSKolomietsVladislav M.KolomietsVladislav M.20173100

With the development of HIV epidemics, the significance of HIV-positive contingents as risk groups for the development of TB increases, and the need of an intensification of preventive measures for these groups increases. The article presents the analysis of the epidemic situation of HIV-associated TB in region. The prevalence of HIV-positive population reached 95,3/100000. The author reveals the features of the prevalence and the clinical course of HIV-associated TB. The morbidity of the HIV-associated TB tends to increase from 0.97 to 1.7/100000. The author analyzes some domestic clinical guidelines and the guidelines of experts of the World Health Organization regarding the use of specific TB prophylaxis among HIV-positive people. As a result, the author recommends to exclude primary chemoprophylaxis in TB-negative patients and to use it as secondary, considering the risk factors, and with the use of no less than two antibacterial drugs in a regimen of test therapy.

With the development of HIV epidemics, the significance of HIV-positive contingents as risk groups for the development of TB increases, and the need of an intensification of preventive measures for these groups increases. The article presents the analysis of the epidemic situation of HIV-associated TB in region. The prevalence of HIV-positive population reached 95,3/100000. The author reveals the features of the prevalence and the clinical course of HIV-associated TB. The morbidity of the HIV-associated TB tends to increase from 0.97 to 1.7/100000. The author analyzes some domestic clinical guidelines and the guidelines of experts of the World Health Organization regarding the use of specific TB prophylaxis among HIV-positive people. As a result, the author recommends to exclude primary chemoprophylaxis in TB-negative patients and to use it as secondary, considering the risk factors, and with the use of no less than two antibacterial drugs in a regimen of test therapy.

epidemic situationchemoprophylaxistuberculosisHIV infectionepidemic situationchemoprophylaxistuberculosisHIV infectionСписок литературыBelyakova N.V. Improving tuberculosis prevention in patients with HIV infection in penitentiary facilities: abstract of a PhD thesis: 14.00.16 М.  2010. 26 p.Kolomiets V.M. Reactivation of lung tuberculosis and its prevention in groups of high-risk: abstract of a doctoral thesis: К., 1982. 28 p.Kolomiets V.M. Penitentiary tuberculosis: Pathomorphosis and efficiency of rehabilitation. Kursk: 2014. 248 p. Nechaeva O.B., Sterlikov S.A., Hurieva N.B. Benchmarks & indicators of the State Program of the development of Russian healthcare up to 2020. Tuberculosis and lung diseases. 2014. №12. Pp. 25-34.Basic results of monitoring and evaluation of HIV-associated tuberculosis in Belarus. /Gurevich G.L., Astravko A.P., Skryagina E.M., Kalechits O.M., Bogomazova A.V. HIV-associated tuberculosis: epidemiological, clinical and social aspects: publication of International scientific-practical conference “HIV – associated tuberculosis: epidemiological, clinical and social aspects” edited by Gurevich G.L. and others. Grodno 2015. Pp. 20-22.Pis’mennaya E.V., Baryshnikova V.A., Sirotkina E.I. Features of evolution of HIV epidemics in Kursk region. Infectious diseases as a multi-disciplinary issue: publication of the all-Russian scientific-practical conference with international participants, Nov. 30, 2016. Ed. by Silina L.V., Kolomiets V.M. Provotorov V.Y. Kursk State Medical University, 2016. Pp.192-197.Ravilogne M., Korobicin A.A. The WHO's new End TB Strategy in the Sustainable Development Goals, contribution of the Russian Federation. Tuberculosis and lung diseases. 2016. №11. Pp. 7-15.Sinitsyn M.V., Belilovskiy E.M., Rybka L.N. HIV-associated Tuberculosis. TB control in Moscow. Analytical review of the statistics indicators, 2015.  Ed. by MD Bogorodskaya E.M., Academician of RAS Litvinov V.I., cand. Belilovskiy E.M. M. MNPCBT. 2016. Pp. 115-133.HIV associated tuberculosis in the Russian Federation  / Nechaeva O.B., Belilovskij E.M., Zagdyn Z.M., Shchukina I.V. Tuberculosis in the Russian Federation  2012/2013/2014. An analytical review of the statistics indicators used by the Russian Federation and in the world М., 2015. Pp. 177-195.Clinical Protocol for the WHO European Region ... Management of coinfected patients with active TB. Clinical management of TB/HIV in special conditions URL: http://www.euro.who.int/__data/assets/pdf_file/0004/78124/ E90840 _Chapter_4.pdf (date of access: December 25, 2016)The Russian Federation manual for tuberculosis prevention, diagnostics & treatment in HIV patients М. 2016. 42 p.Frolova O.P. The epidemic situation of tuberculosis in HIV/AIDS patients in the Russian Federation and its prevention system. The problems of tuberculosis, 2001. №5. Pp. 31-34.Phthisiology. National handbook/ Edited by Perelman. М. GEOTAR Media, 2007. 512 p.Tsybikova E.B., Zubova N.A. TB chemoprophylaxis in HIV/AIDS patients in the regions of the Russian Federation with high levels of HIV infection. Tuberculosis and lung diseases. 2016. Vol. 94. №2. Pp.16-24.Akolo C, Adetifa I, Shepperd S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons.Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD000171.DOI: 10.1002/14651858.CD000171.pub3Centers of Disease Control and Prevention. Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent Mycobacterium tuberculosis infection. MMWR Morb. Mortal. Wkly Rep. 2011. Vol. 60. № 48. Pp. 1650-1653.World Health Organization. Preventive therapy against tuberculosis in people living with HIV. Weekly Epidemiological Record. 1999. Vol. 74. Pp. 385-398.